? PILOT AND FEASIBILITY PROGRAM The Pilot Feasibility Program seeks to introduce new investigators and ideas to the Liver Center, to promote novel ideas that may advance the field of hepatology, and to enable investigators to obtain data for future grant submissions, such as R01 applications. Candidates for funding in order of priority consist of: (1) senior postdoctoral fellows and junior faculty; (2) established University investigators in other fields who wish to apply their areas of expertise to subjects of Center interest; and (3) Center members who wish to pursue a project that is different from their current focus of interest and who need to develop preliminary data to apply for new R01-type funding. Despite limited and essentially level funding for this program during the past 31 years, this component of the Center has provided us with an annual opportunity to solicit applications for pilot project awards from throughout the Yale community. This has enabled the Center to continually revitalize its membership and to capitalize on new technologies and research opportunities of importance to the continued development of the Center's research base. For example, during the past 6 years this program has enabled the Center to bring new investigators into the Center with expertise in diverse but cutting-edge areas. Pilot Feasibility projects also were pivotal for the development of novel technologies such as iPSC-derived cholangiocytes, as well as biliary organoids derived from liver tissue or bile. The program has been successful by a variety of other metrics: awardees over the past 11 years published 66 manuscripts as a direct result of their funding and competed successfully for 36 new grants, representing a 17-fold return on investment. In addition, 45 of the 46 awardees (including those who left Yale) remain involved in digestive diseases-related research. Moreover, in the last 12 years (including grants that were just awarded September 2019), 73% of the 37 Pilot/Feasibility awardees who are still at Yale remain active Center members.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK034989-36A1
Application #
10048273
Study Section
Special Emphasis Panel (ZDK1)
Project Start
1997-09-30
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
36
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Garcia-Tsao, Guadalupe (2018) Regression of HCV cirrhosis: Time will tell. Hepatology 67:1651-1653
Hung, Adelina; Garcia-Tsao, Guadalupe (2018) Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. Liver Int 38:1437-1441
Kaffe, Eleanna; Fiorotto, Romina; Pellegrino, Francesca et al. (2018) ?-Catenin and interleukin-1?-dependent chemokine (C-X-C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis. Hepatology 67:1903-1919
Goldberg, David S; Levy, Cynthia; Yimam, Kidist et al. (2018) Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clin Gastroenterol Hepatol 16:591-593
Cadamuro, Massimiliano; Stecca, Tommaso; Brivio, Simone et al. (2018) The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864:1435-1443
Besse, Whitney; Choi, Jungmin; Ahram, Dina et al. (2018) A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Hum Mutat 39:378-382
Strazzabosco, Mario; Fiorotto, Romina; Cadamuro, Massimiliano et al. (2018) Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. Biochim Biophys Acta Mol Basis Dis 1864:1374-1379
Murugesan, Vagishwari; Liu, Jun; Yang, Ruhua et al. (2018) Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. Blood Cells Mol Dis 68:47-53
Sachar, Hamita; Pichetshote, Nipaporn; Nandigam, Kavitha et al. (2018) Continued midazolam versus diphenhydramine in difficult-to-sedate patients: a randomized double-blind trial. Gastrointest Endosc 87:1297-1303
Bhutta, A Q; Garcia-Tsao, G; Reddy, K R et al. (2018) Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther 47:78-85

Showing the most recent 10 out of 763 publications